Sanofi-Aventis plans Multaq NDA resubmission in 2008
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA issued a "not approvable" letter for Sanofi-Aventis' Multaq (dronedarone) for treatment of atrial fibrillation/atrial flutter on Aug. 31. The company says it will resubmit the NDA in 2008 to include data from the ongoing ATHENA trial. Sanofi recently expanded the ATHENA sample size from 3,700 to 4,300 patients to attain the planned event rates. The dronedarone NDA was submitted in June 2005 based on the EURIDIS and ADONIS trials (1Pharmaceutical Approvals Monthly December 2005, p. 10)...
You may also be interested in...
Sanofi-Aventis Eyes April User Fee Goal For Anti-Arrythmic Dronedarone
In advance of an April user fee deadline for Sanofi-Aventis’ anti-arrythmic dronedarone, the firm is positioning the compound as a successor to its Cordarone (amiodarone) with increased tolerability.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.